Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Diversified Trust Co lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 40.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,482 shares of the biopharmaceutical company's stock after selling 999 shares during the quarter. Diversified Trust Co's holdings in Alnylam Pharmaceuticals were worth $400,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares during the period. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $28,000. Whipplewood Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the period. Finally, OFI Invest Asset Management bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. BMO Capital Markets increased their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. HC Wainwright reissued a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Morgan Stanley cut their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Finally, UBS Group boosted their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $340.00.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded up $2.17 during trading on Thursday, reaching $331.94. The company's stock had a trading volume of 431,036 shares, compared to its average volume of 854,368. The firm has a market cap of $43.28 billion, a price-to-earnings ratio of -158.82 and a beta of 0.23. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The firm has a 50 day moving average of $291.57 and a 200-day moving average of $264.87. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $334.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.